63. 特発性血小板減少性紫斑病 Idiopathic thrombocytopenic purpura Clinical trials / Disease details


臨床試験数 : 363 薬物数 : 217 - (DrugBank : 43) / 標的遺伝子数 : 45 - 標的パスウェイ数 : 137

  
2 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2019-004103-12-IT
(EUCTR)
24/07/202021/01/2021A Study to Evaluate Safety, Tolerability and Efficacy of TAK-079 in Patients with Immune ThrombocytopeniaA Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Safety, Tolerability and Efficacy of TAK-079 in Patients with Persistent/Chronic Primary Immune Thrombocytopenia - / Primary immune thrombocytopenia
MedDRA version: 23.0;Level: LLT;Classification code 10050245;Term: Autoimmune thrombocytopenia;System Organ Class: 100000004851;Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]
Product Name: TAK-079
Product Code: [TAK-079]
INN or Proposed INN: TAK-079
Product Name: difenidramina
Product Code: [NA]
INN or Proposed INN: DIFENIDRAMINA CLORIDRATO
Other descriptive name: dyphenhydramine hydrochloride
Product Name: paracetamolo
Product Code: [acetominofene]
INN or Proposed INN: PARACETAMOLO
Other descriptive name: acetominophen
Product Name: metilprednisolone
Product Code: [/]
INN or Proposed INN: METILPREDNISOLONE
Other descriptive name: methylprednisolone
MILLENNIUM PHARMACEUTICALS, INC.NULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
54Phase 2United States;Slovenia;Ukraine;Croatia;Bulgaria;Germany;Italy
2ChiCTR-IIR-16008994
2016-09-012016-08-08Safety and efficacy analysis of two conventional dosage regimens Methylprednisone for initial treatment of primary immune thrombocytopenia:A multicenter randomized controlled clinical trialSafety and efficacy analysis of two conventional dosage regimens Methylprednisone for initial treatment of primary immune thrombocytopenia:A multicenter randomized controlled clinical trial Primary immune thrombocytopeniathe short-course group (Group A):Oral methylprednisolone for 2 weeks, the initial dosage is 0.8mg/kg/d, than reduces to 0.4mg/kg/d for 1 week, than to 0.2mg/kg/d for 1 week, than stop.;the long-course treatment group (Group B):Oral methylprednisolone for 1 month, the initial dosage is 0.8mg/kg/d,than reduces to 0.4mg/kg/d for 1 month, than to 0.1mg/kg/d for 2 week, than stop.;Institute of Hematology & Blood Diseases Hospital Chinese Academy of Medical Sciences & Peking Union Medical CollegeNULLPending1860Boththe short-course group (Group A):150;the long-course treatment group (Group B):150;4 (Phase 4 study)China